PB1773: AML AND MDS WITH RARA OVEREXPRESSION: MOLECULAR AND CLINICAL FEATURES OF PATIENTS ENROLLED IN A PHASE 2 TRIAL EVALUATING TAMIBAROTENE-BASED THERAPY

por de Botton, Stéphane, Cluzeau, Thomas, Vigil, Carlos, Cook, Rachel, Rousselot, Philippe, Rizzieri, David, Liesveld, Jane, Fenaux, Pierre, Braun, Thorsten, Pigneux, Arnaud, Peterlin, Pierre, Paul, Sofia, Rajagopal, Nisha, Carulli, John, Roth, David, Volkert, Angela, Malak, Tanya Abdul, Kelly, Michael, Klimek, Virginia, Stein, Eytan
Publicado 2023